Astra's Lynparza Boosts Survival in Ovarian Cancer Patients

(Bloomberg) -- Ovarian cancer patients gain an estimated three years before their tumors worsen when they take Lynparza, a drug from AstraZeneca Plc and Merck & Co., according to a study that docto...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.